Menu Search
Equities

LivaNova PLC

RIJ:DEU

LivaNova PLC

Actions
  • Price (EUR)38.60
  • Today's Change-0.20 / -0.52%
  • Shares traded0.00
  • 1 Year change-45.25%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2023 13:38 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

LivaNova PLC is a medical device company focused on the development and delivery of important products and therapies for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The Company designs, develops, manufactures and sells products and therapies to provide improvements for both the head and heart. The Company operates in three reportable segments: Cardiopulmonary, Neuromodulation and Advanced Circulatory Support. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.

  • Revenue in USD (TTM)1.02bn
  • Net income in USD-86.25m
  • Incorporated2015
  • Employees2.90k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		LIVN:NSQ since
announced		Transaction
value
ALung Technologies IncDeal completed02 May 202202 May 2022Deal completed-44.56%110.00m
Data delayed at least 15 minutes, as of Mar 27 2023 21:00 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.